https://cacm.acm.org/research/can-we-measure-the-impact-of-a-database/
Can We Measure the Impact of a Database?
If we want to measure the impact of a database, can we use its organization to treat it the same way we treat any other publishing agent, such as a journal or an author?
By Peter Buneman, Dennis Dosso, Matteo Lissandrini, Gianmaria Silvello, and He Sun
Posted Apr 16 2025
H-index for DB level
the secret superfood new scientist
Most ingredients touted as the key to better health fail to live up to the hype but fibre bucks this trend, with benefits for the whole body, not just the gut
for Fibre, best with 25g/day
https://www.newscientist.com/article/mg26535362-500-the-ozempic-era-is-only-just-beginning/
The Ozempic era is only just beginning
In the past year, treatments such as Wegovy, Mounjaro and Zepbound have become household names. But there are many questions left to answer, not least what the future holds for weight-loss medications and society at large
https://pubs.acs.org/doi/10.1021/cen-10311-cover
QT:{{”
Modalities
Here are some of the modalities that medicinal chemists can choose among when they set out to interrupt the function of a disease-related protein or other biomolecule.
Competitive inhibitors: Mimic a substrate and occupy the active site of an enzyme
Allosteric modulators: Bind somewhere other than the active site to influence an enzyme’s action
Covalent inhibitors: Covalently bind to a target protein, and change its conformation to block activity
PROTACs and other bifunctional molecules: Bind to two different proteins to drive outcomes such as protein degradation
Molecular glues:Stabilize the interface between two proteins—often aiming to degrade one of the two
Splice modifiers: Change the alternative splicing of an RNA molecule, affecting how the related protein is made
Monoclonal antibodies: Bind to targets on the cell surface with high specificity Bispecific antibodies: Modified to bind to two different targets Antibody-drug conjugates: Deliver drugs (usually chemotherapies) to cells specified by an antibody
Antibody fragments and light-chain antibodies: Bind to specific epitopes, but are smaller than a monoclonal antibody
Peptides: Usually bind to receptors, mimicking hormones
Cyclic peptides: Act as linear peptides do, but with smaller 3D structure, offering large-molecule specificity but lower degradation CRISPR and related technologies: Alter DNA encoding disease-related proteins Interfering RNA and antisense oligonucleotides: Block production of proteins from RNA
RNA aptamers: Bind to target molecules, sometimes used to block or activate signaling
mRNA: Introduces desired proteins to be made
RNA editors:Alter a target RNA by one or a few bases to change protein sequence Cell therapies: Bind to and kill specific cells, usually recognizing cancer epitopes
“}}
Mounting evidence suggests there might be two separate types of the world’s fastest-growing neurological condition. Can this fresh understanding lead to much-needed new treatments?
By Alexandra Thompson
RBD – REM disorder
very interesting paper which compares neuroscience
experiments to AI LLM and foundation models:
https://www.nature.com/articles/s42256-025-01049-z
linkstream2 microblog 